Tofacitinib (7) (Xeljanz®) – Ankylosing spondylitis (AS)
Characteristics
| Start date | 15.12.2021 |
|---|---|
| Resolution | 16.06.2022 |
| INN | Tofacitinib |
| Brand name | Xeljanz® |
| Pharm. company | Pfizer Pharma GmbH |
| G-BA procedure ID | 2021-12-15-D-764 |
| Therapeutic area | Musculoskeletal system diseases |
| Reason for procedure | New Indication |
| Indication (German) |
|---|
|
Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy |
| Subpopulation | Indication | Comparator |
|---|---|---|
| a1) | Adults with active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy and who are eligible for treatment with tofacitinib. | A TNF-α inhibitor (adalimumab or certolizumab pegol or etanercept or golimumab or infliximab) or an IL17 inhibitor (secukinumab). |
| a2) | Adults with active ankylosing spondylitis (AS)who have responded inadequately to previous therapy with biological with biologic antirheumatic drugs (bDMARDs) or who are intolerant to these drugs and who are or who are intolerant to them and who are eligible for treatment with tofacitinib. | Switching to another biological disease-modifying antirheumatic drug: TNF-α inhibitor (adalimumab or certolizumab pegol or etanercept or golimumab or infliximab) or IL17 inhibitor (secukinumab). |
9. Associated procedures
<< List of all resolutions